|

Semaglutide, 1.0 mg/mL Clinical Trials

2 actively recruiting trials

Also known as: OZEMPIC

Pipeline

Phase 2: 1

Top Sponsors

  • University Health Network, Toronto1
  • Attikon Hospital1

Indications

  • Diabetes2
  • Liver Disease1
  • Kidney Transplant Recipients1
  • Diabetes Type 21

Other2 trials

The Effect of Semaglutide on Cardiovascular Markers and Liver Function
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.